EC Number   |
|---|
   2.1.1.103 | D128A mutant in complex with S-adenosylhomocysteine and either phosphoethanolamine or phosphocholine, hanging drop vapor diffusion method, using 20% (w/v) PEG 8000, 0.1 M sodium cacodylate (pH 6.5), 0.2 M sodium acetate, 20 mM tris(2-carboxyethyl)phosphine, and 5 mM S-adenosyl-L-homocysteine |
| 2.1.1.103 | hanging drop vapor diffusion method, using 100 mM Na-acetate (pH 5.0), and 20% (w/v) PEG 3350 |
| 2.1.1.103 | in complex with amodiaquine, hanging drop vapor diffusion method |
| 2.1.1.103 | in complex with either S-adenosyl-L-methionine (1), phosphoethanolamine (2), phosphocholine (3), sinefungin (4), or both phosphoethanolamine and S-adenosylhomocysteine (5), hanging drop vapor diffusion method, using (1) 20% (w/v) PEG-8000, 0.1 M sodium cacodylate, pH 6.5, 0.2 M sodium acetate, 20 mM tris(2-carboxyethyl) phosphine, or (2-5) 20-30% (w/v) PEG8000, 0.1 M sodium cacodylate,pH 6.5, 0.2 M sodium acetate, 5 mM 2-mercaptoethanol |
| 2.1.1.103 | molecular docking of inhibitors N-[5-[(9,10-dimethoxy-4-oxo-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-2-yl)amino]pentyl]propanamide and (3S)-1-(4-hydroxyphenyl)-N-[(2S)-1-[[2-(1H-indol-3-yl)ethyl]amino]-1-oxopropan-2-yl]-5-oxopyrrolidine-3-carboxamide. Both inhibitors form hydrogen interactions with crucial tyrosine residues and also crucial amino acids of phosphatidylcholine binding site |
| 2.1.1.103 | sitting drop vapor diffusion method, using 200 mM NH4-formate and 20% (w/v) PEG 3350 |
| 2.1.1.103 | structure in complex with S-adenosyl-L-methionine |
| 2.1.1.103 | structure in complex with S-adenosyl-L-methionine, to 1.5 A resolution |
